CEO Thomas Lingelbach comments on Valneva’s strategic partnership to accelerate the development of the world’s most clinically advanced tetravalent Shigella vaccine candidate. https://lnkd.in/eF8gTVDR
Valneva
Recherche en biotechnologie
Saint-Herblain, Pays de la Loire 35 827 abonnés
Specialty vaccine company focused on prevention of infectious diseases with major unmet need, such as Lyme & chikungunya
À propos
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 700 employees.
- Site web
-
http://www.valneva.com
Lien externe pour Valneva
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 501-1 000 employés
- Siège social
- Saint-Herblain, Pays de la Loire
- Type
- Société cotée en bourse
- Fondée en
- 2013
- Domaines
- vaccines
Lieux
Employés chez Valneva
Nouvelles
-
Valneva and LimmaTech enter into a strategic partnership to accelerate the development of the world’s most clinically advanced tetravalent Shigella vaccine candidate. https://lnkd.in/eF8gTVDR
-
Valneva a republié ceci
Attention Health Care Providers - Although most surveillance-reported cases of Lyme disease in the US are in people who are White, data suggest worse outcomes among people from racial and ethnic minority groups. A recent systematic literature review from Pfizer and development partner Valneva highlights the need for further research and improved surveillance data to address these gaps. Read the full publication in Zoonoses and Public Health here: https://bit.ly/3KuechB
-
Valneva CEO Thomas Lingelbach comments on the expanded partnership with CEPI and the announcement of its $41.3 million grant to support broader access to the world’s first chikungunya vaccine. More details here: https://lnkd.in/ejAPk7JP
-
CEPI expands partnership with Valneva with a $41.3 million grant to support broader access to the World’s first chikungunya vaccine. https://lnkd.in/ejAPk7JP
-
Valneva CMO Dr. Juan Carlos Jaramillo comments on the Primary Vaccination Series Completion of Phase 3 VALOR Lyme Disease Trial. More details here: https://lnkd.in/e8Nk-v-4
-
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion. https://lnkd.in/e8Nk-v-4
-
Renowned, peer-reviewed medical journal, The Lancet Infectious Diseases has published Phase 2 immunogenicity and safety results of an 18-month booster dose of Valneva and Pfizer’s Lyme disease vaccine candidate after primary immunisation in healthy adults in the USA. Read more here: https://lnkd.in/d95gFX7q
-
This month, one of the largest sporting events in the world is set to kick off in Paris, with millions of people expected to descend upon the region. While this is an exciting time that brings together people from all over the globe, such mass gatherings can pose potential public health risks, including the spread of infectious diseases transmitted by mosquitos. Read this insightful article by Dr. Juan Carlos Jaramillo, our Chief Medical Officer, on the growing risk of mosquito-borne diseases and essential preparation and prevention measures below. https://rb.gy/ekffdz #MosquitoBorneDiseases #infectiousdisease #Paris #Olympics #publichealth #AdvancingVaccinesForBetterLives
-
Meet the #Valneva team! Adrianne is our Global Market Access Manager. She works collaboratively with different teams, focusing on research through literature and health economic studies. With expert team members like Adrianne, we continue to make significant progress in advancing a wide range of vaccine candidates for infectious diseases associated with significant unmet medical needs. Check out Adrianne’s interview to learn more about her role and why she enjoys working at Valneva. #EmployeeSpotlight #Vaccines #PublicHealth #AdvancingVaccinesForBetterLives